| In December 2019, novel coronavirus caused pneumonia outbroke in Wuhan, Hubei Province, China. It was named coronavirus disease 2019 (COVID-19). Up to 24:00 March 1, 2020, according to reports from 31 provinces (autonomous regions, municipalities) and the Xinjiang Production and Construction Corps, there have been a total of 80 026 confirmed cases in mainland China and 148 confirmed cases in Hong Kong, Macao, and Taiwan regions of China. Currently, there are still no targeted specific antiviral drugs or vaccines for COVID-19. The drugs are selected mainly based on the previous treatment experience, such as severe acute respiratory syndrome, Middle East respiratory syndrome and some other influenza virus. Remdesivir, chloroquine, favipiravir, and convalescent plasma are clinically effective. However their safety and efficacy require further verifications in large sample size. For combined application of ribavirin, lopinavir/ritonavir, interferon-α and arbidol, more attentions should be paid to adverse reactions and the combination should be selected with caution. Darunavir is currently in vitro experiments, and TCM dialectical treatment should be further verified. This article reviews the current clinical research progress on the medication of COVID-19, so as to provide evidence for COVID-19 treatment. |